GLP1R and inflammatory bowel disease: Meta-analysis showed no effect of GLP1-RA on advanced therapy initiation (ie, biologicals and/or small molecule therapies) in IBD (logHR: 0.96, 95% CI: 0.74-1.23, I2 = 15%, P = 0.72) ­(Figure 3).